Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Immunome Inc.IMNM · Entity 4219 | Chief Technology Officer | December 13, 2023 | December 15, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Immunome Inc.
Report date December 13, 2023 · Filed December 15, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.34 · Expires 2033-12-12 | Direct | 275,000 |
Reported balance
After 2023-12-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-12-13 · Grant · Acquired 275,000 · Balance 275,000 F1: 25% of the shares subject to the options vest on December 8, 2024, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to the options vest on December 8, 2024, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 13, 2023 Filed Dec 15, 2023 19:28 UTC | Immunome Inc. IMNM · Entity 4219 | GrantStock option (right to buy) · Derivative | 275,000 | $0.00 Strike: $7.34 | $0.00 |
DisclosureSEC source: 0001209191-23-058886 · doc4.xml · derivative · entry 1 Roberts Phil Noland · CIK 0002004455 · Chief Technology Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2033-12-12 F1 · derivative.exercise_date: 25% of the shares subject to the options vest on December 8, 2024, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.